August 16, 2017
Nordic Nanovector: - Nordic Nanovector ASA: Invitation to Second Quarter 2017 Results Presentation and Webcast
(Press Release 31/2017). See link for details

August 14, 2017
Nordic Nanovector: - NORDIC NANOVECTOR TO HOST CAPITAL MARKETS DAY IN OSLO ON 22 NOVEMBER 2017
(Press Release 30/2017). See link for details

August 10, 2017
Nordic Nanovector: - Nordic Nanovector to Present at Wedbush PacGrow Healthcare Conference
(Press Release 29/2017). See link for details

August 2, 2017
Nordic Nanovector: - Nordic Nanovector Appoints Dr. Reza Safaei as Head of Medical Affairs
(Press Release 28/2017). See link for details

July 10, 2017
Nordic Nanovector: - Nordic Nanovector ASA: Increase of share capital/mandatory notification of trade
(Press Release 27/2017). See link for details

July 5, 2017
Nordic Nanovector: - Nordic Nanovector ASA: Mandatory notification of trade - primary insider
(Press Release 26/2017). See link for details

June 22, 2017
Nordic Nanovector: - Nordic Nanovector ASA: Mandatory notification of trade - primary insider
(Press Release 25/2017). See link for details

June 19, 2017
Nordic Nanovector: - Nordic Nanovector to present to investors at the Citi European Healthcare Conference
(Press Release 24/2017). See link for details

June 14, 2017
Nordic Nanovector: - Single dose Betalutin® continues to show promising efficacy and safety in recurrent indolent NHL patients
(Press Release 23/2017). See link for details

June 13, 2017
Nordic Nanovector: - Invitation to Conference Call for Updated Clinical Trial Results reported at the International Conference on Malignant Lymphoma
(Press Release 22/2017). See link for details

June 9, 2017
Nordic Nanovector: - Nordic Nanovector to be included in Oslo Børs OBX Index
(Press Release 21/2017). See link for details

June 7, 2017
Nordic Nanovector: - Accepted abstract by ICML with updated results from Phase 1/2 trial of Betalutin® in NHL is now available on-line
(Press Release 20/2017). See link for details

June 2, 2017
Nordic Nanovector: - Nordic Nanovector ASA: Allocation of restricted stock unites (RSUs) to the board of directors
(Press Release 19/2017). See link for details

June 2, 2017
Nordic Nanovector: - Nordic Nanovector to Present at Jefferies Healthcare Conference in New York on Thursday June 8th
(Press Release 18/2017). See link for details

May 24, 2017
Nordic Nanovector: - Nordic Nanovector ASA: Annual General Meeting held
(Press Release 17/2017). See link for details
See: Minutes of Annual General Meeting 2017 with appendices

May 24, 2017
Nordic Nanovector: - Nordic Nanovector ASA – Results for First Quarter 2017
(Press Release 16/2017). See link for details
See: Q1 2017 Report
See: Q1 2017 Presentation

May 24, 2017
Nordic Nanovector: - Nordic Nanovector ASA - resultater for første kvartal 2017
(Press Release 17/2017). See link for details
See: Q1 2017 Presentation
See: Q1 2017 Report

May 19, 2017
Nordic Nanovector: - Safety Review Committee Approves the Continued Evaluation of the 20 MBq/kg Betalutin® with 100 mg/m2 Lilotomab Regimen in Phase 2 Cohort in NHL
(Press Release 15/2017). See link for details

May 16, 2017
Nordic Nanovector: - Nordic Nanovector ASA: Invitation to First Quarter 2017 Results Presentation and Webcast
(Press Release 14/2017). See link for details

May 2, 2017
Nordic Nanovector: - Nordic Nanovector ASA: Notice of Annual General Meeting on 24 May 2017
(Press Release 13/2017). See link for details
See: Notice of the Annual General Meeting

April 28, 2017
Nordic Nanovector: - Updated results from Phase 1/2 trial of Betalutin® in NHL accepted for presentation at the International Conference on Malignant Lymphoma in June
(Press Release 12/2017). See link for details

April 27, 2017
Nordic Nanovector: - Nordic Nanovector to Present at Upcoming Deutsche Bank and Jefferies Healthcare Conferences
(Press Release 11/2017). See link for details

March 27, 2017
Nordic Nanovector: - NORDIC NANOVECTOR ASA - FINANCIAL CALENDAR
(Press Release 10/2017). See link for details

March 24, 2017
Nordic Nanovector: - Nordic Nanovector publishes Annual Report 2016
(Press Release 9/2017). See link for details
See: Annual Report 2016

March 17, 2017
Nordic Nanovector: - Nordic Nanovector announces first patient dosed in Phase 1 study of Betalutin® in diffuse large B-cell lymphoma (DLBCL), an aggressive form of NHL
(Press Release 8/2017 ). See link for details

February 28, 2017
Nordic Nanovector: - Nordic Nanovector ASA – Results for Fourth Quarter and Full Year 2016
(Press Release 6/2017). See link for details
See: Q416 report 2016
See: Q4 16 presentation 2016

February 28, 2017
Nordic Nanovector: - Nordic Nanovector ASA – resultater for fjerde kvartal og helår 2016
(Press Release 7/2017). See link for details
See: Q4 16 presentation 2016
See: Q416 report 2016

February 22, 2017
Nordic Nanovector: - Nordic Nanovector ASA: Invitation to Fourth Quarter and Full Year 2016 Results Presentation and Webcast
(Press Release 5/2017). See link for details

February 2, 2017
Nordic Nanovector: - Nordic Nanovector ASA: Share capital increase registered
(Press Release 4/2017). See link for details

February 2, 2017
Nordic Nanovector: - Nordic Nanovector: Share options granted, including options to primary insiders
(Press Release 3/2017). See link for details

January 24, 2017
Nordic Nanovector: - Nordic Nanovector ASA: Exercise of employee share options and increase of share capital
(Press Release 2/2017). See link for details

January 4, 2017
Nordic Nanovector: - Nordic Nanovector to Present at Biotech Showcase 2017
(Press Release 1/2017). See link for details